Biomaterial Database

The effect of low-dose epsilon-aminocaproic acid on patients following coronary artery bypass surgery. 1996

R M Montesano, and P A Gustafson, and D A Palanzo, and N J Manley, and F S Sadr

Lehigh Valley Hospital, Allentown, Pennsylvania 18105, USA.

The effect of low-dose epsilon-aminocaproic acid (EACA) on the postoperative course of 46 patients was studied. Patients undergoing coronary artery bypass grafting were randomly selected in two groups. Group 1 (20 patients) received 5 g EACA upon initiation of cardiopulmonary bypass (CPB). Group 2 (26 patients) received no antifibrinolytic drugs prior to CPB. Neither group received antifibrinolytic drugs after CPB. There was no significant difference between the two groups' blood usage on CPB: 0.65 units in Group 1 and 0.60 units in Group 2. After CPB, blood usage significantly differed: 2.2 +/- 1.7 (SD) units in Group 1 and 3.9 +/- 3.0 units in Group 2 (p = 0.033). Significant difference was also demonstrated in postoperative blood loss in the first 24 hours: 1610 +/- 531 ml in Group 1 versus 2025 +/- 804 ml in Group 2 (p = 0.043). Pre-CPB administration of low-dose EACA significantly decreases blood loss and blood usage in the postoperative period.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000933	Antifibrinolytic Agents	Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders.	Antifibrinolysin,Antifibrinolysins,Antifibrinolytic,Antifibrinolytic Agent,Antiplasmin,Antiplasmins,Antifibrinolytics,Plasmin Inhibitor,Plasmin Inhibitors,Agent, Antifibrinolytic,Agents, Antifibrinolytic,Inhibitor, Plasmin,Inhibitors, Plasmin
D001026	Coronary Artery Bypass	Surgical therapy of ischemic coronary artery disease achieved by grafting a section of saphenous vein, internal mammary artery, or other substitute between the aorta and the obstructed coronary artery distal to the obstructive lesion.	Aortocoronary Bypass,Bypass, Coronary Artery,Bypass Surgery, Coronary Artery,Coronary Artery Bypass Grafting,Coronary Artery Bypass Surgery,Aortocoronary Bypasses,Artery Bypass, Coronary,Artery Bypasses, Coronary,Bypass, Aortocoronary,Bypasses, Aortocoronary,Bypasses, Coronary Artery,Coronary Artery Bypasses
D012189	Retrospective Studies	Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.	Retrospective Study,Studies, Retrospective,Study, Retrospective
D015119	Aminocaproic Acid	An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.	6-Aminocaproic Acid,6-Aminohexanoic Acid,epsilon-Aminocaproic Acid,Amicar,CY-116,Capralense,Capramol,Caproamin,Caprocid,Caprolest,Epsamon,Epsikapron,Hemocaprol,Hexalense,6 Aminocaproic Acid,6 Aminohexanoic Acid,CY 116,CY116,epsilon Aminocaproic Acid
D019106	Postoperative Hemorrhage	Hemorrhage following any surgical procedure. It may be immediate or delayed and is not restricted to the surgical wound.	Blood Loss, Postoperative,Hemorrhage, Postoperative,Hemorrhages, Postoperative,Postoperative Hemorrhages,Loss, Postoperative Blood,Postoperative Blood Loss

Related Publications

R M Montesano, and P A Gustafson, and D A Palanzo, and N J Manley, and F S Sadr

Epsilon-aminocaproic acid administration and stroke following coronary artery bypass graft surgery.

May 1999, The Annals of thoracic surgery,

R M Montesano, and P A Gustafson, and D A Palanzo, and N J Manley, and F S Sadr

Epsilon-aminocaproic acid in coronary artery bypass graft surgery: preincision or postheparin?

December 2003, Anesthesiology,

R M Montesano, and P A Gustafson, and D A Palanzo, and N J Manley, and F S Sadr

A randomized trial of the topical effect of antifibrinolytic epsilon aminocaproic Acid on coronary artery bypass surgery without cardiopulmonary bypass.

September 2014, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis,

R M Montesano, and P A Gustafson, and D A Palanzo, and N J Manley, and F S Sadr

The use of low-dose aprotinin, epsilon-aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations.

April 1997, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,

R M Montesano, and P A Gustafson, and D A Palanzo, and N J Manley, and F S Sadr

Pharmacokinetics of epsilon-aminocaproic acid in patients undergoing aortocoronary bypass surgery.

June 1999, Anesthesiology,

R M Montesano, and P A Gustafson, and D A Palanzo, and N J Manley, and F S Sadr

The use of epsilon-aminocaproic acid to reduce bleeding following coronary artery revascularization.

April 1977, The Alabama journal of medical sciences,

R M Montesano, and P A Gustafson, and D A Palanzo, and N J Manley, and F S Sadr

The effect of prophylactic epsilon-aminocaproic acid on bleeding, transfusions, platelet function, and fibrinolysis during coronary artery bypass grafting.

August 1999, Anesthesiology,